ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SSII / forecast
CERS (27) RCEL (46) BWAY (44) DCTH (59) ⌘ Pro Terminal →

SS Innovations International Inc. (SSII) 12-Month Stock Forecast & Price Target Cone

$2.31 -1.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.30

SS Innovations International Inc. (SSII) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $471.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SSII Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SSII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SS Innovations International Inc. (NASDAQ: SSII) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.31 (-1.70% 1D, market cap $471.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SSII ranks #792 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SSII compare to CERS and RCEL in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), SSII carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 46.0%, and ROIC of -18.5%. By comparison, CERS (Cerus Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -15.5%, cap $459.5M) and RCEL (Avita Medical Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $484.0M). Among the 5-stock peer group, SSII leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SSII?
▼

Per SSII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676163), SS Innovations International Inc. generated $42.5M in revenue (+105.7% YoY), -$12.1M in net income, and -$22.2M in free cash flow against $74.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.30 (-0.50%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (5)Whales (3)SEC (14)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$9 Bull$2 Base$2 Bear
📬 FREE SSII RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SSII)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY SSII SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (47% of score)

Altman Z-Score 7.47 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (17% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 46% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$2.55-0.4% Next Q
Q2 (-2Q)
35
Grade E$2.54-1.6% Next Q
Q3 (-1Q)
33
Grade E$2.50-7.6% Next Q
Current
30
Grade E$2.31-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SSII Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SSII currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.91) and Max Pain ($2.43) forces dealer call-delta covering toward $8.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SSII• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SSII Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SSII Position Size: $10,000

Shares at $2.31: 4329.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.58
$6,840
$-3,160 (-31.6%)
12M Consensus BaseTarget $2.02
$8,745
$-1,255 (-12.6%)
12M Bull Case BreakoutTarget $8.61
$37,273
+$27,273 (+272.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$869%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SSII)

  • ✓Walkthrough of SSII's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SSII // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.96%▼ DESCENDING CHANNEL
2026-11-03O $2.38H $2.38L $2.31C $2.31VOL 49.7K
RES: $3.76SUP: $2.08SMA50: $2.91SMA200: $3.85
$6.17$5.09$4.02$2.94$1.87RES $3.76SUP $2.08$2.312026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SSII Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SSII Butterfly Map → + Track SSII →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +105.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SSII today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SSII. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SSII today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SSII)

Health Care Rank #792 of 1015 ⚔️ CERS vs SSII Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SSII vs. CERS, RCEL, BWAY, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SS Innovations International Inc. (SSII) ranks #792 by composite RQD confidence (30/100, grade E) and #455 by equity capitalization ($471.1M). Within this direct 5-issuer industry benchmark cohort, SSII leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with SSII at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SSII ACTIVE
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.70% $471.1M Benchmark Subject
CERS
Cerus Corporation
E 27/100 — — -15.5% +3.51% $459.5M /cers-vs-ssii →
RCEL
Avita Medical Inc.
D 46/100 — 82.1% -35.0% -1.53% $484.0M /rcel-vs-ssii →
BWAY
BrainsWay Ltd.
D 44/100 — — — -2.38% $455.9M /bway-vs-ssii →
DCTH
Delcath Systems Inc.
C- 59/100 — 86.2% 0.8% +1.78% $487.2M /dcth-vs-ssii →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001676163 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SS Innovations International Inc. (SSII) reported GAAP revenue of $42.5M (+105.7% vs. FY2024 revenue of $20.6M , and +623.1% cumulative change since FY2023) , GAAP net income of -$12.1M, operating cash flow of -$18.5M, and free cash flow of -$22.2M (-118.4% YoY). On the balance sheet, SSII closed FY2025 with $74.2M in total assets against $0 in total debt (Altman Z-Score: 7.47, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $42.5M -$12.1M -$18.5M -$22.2M $74.2M —
FY2024 (FY) 2024-12-31 $20.6M -$19.2M -$9.5M -$10.2M $42.4M —
FY2023 (FY) 2023-12-31 $5.9M -$20.9M -$15.4M -$15.4M — —

3. SSII Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SSII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SS Innovations International Inc. (NASDAQ: SSII) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.31 (-1.70% 1D, market cap $471.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SSII ranks #792 in composite RQD confidence.

How does SSII compare to CERS and RCEL in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SSII carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 46.0%, and ROIC of -18.5%. By comparison, CERS (Cerus Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -15.5%, cap $459.5M) and RCEL (Avita Medical Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $484.0M). Among the 5-stock peer group, SSII leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SSII?

Per SSII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676163), SS Innovations International Inc. generated $42.5M in revenue (+105.7% YoY), -$12.1M in net income, and -$22.2M in free cash flow against $74.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SSII trading relative to its 50-day, 200-day, and 52-week technical levels?

SSII last traded at $2.31 (-1.70% on volume of 84,899 shares), positioning the stock -20.62% below its 50-day simple moving average ($2.91) and -40.00% below its 200-day simple moving average ($3.85). Across its 52-week range of $2.20 to $8.20, SSII sits at the 1.8% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.02 to $2.60).

Direct Sub-Reports: SSII RQD Cockpit SSII 12M Forecast SSII Earnings & Move SSII Dividends & DRIP SSII Insiders & 13F SSII Whale Options SSII Profit Sankey SSII News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

SSII — SS Innovations International Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SS Innovations International Inc. (SSII) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.31 (-1.70% 1D, market capitalization $471.1M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -18.5%, gross margin of 46.0%, operating margin of -19.3%, and free cash flow yield of -4.65%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 7.47, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Per the news wire, the company is associated with telerobotic surgery, including the SSi Mantra Surgical Robotic System for which an FDA response was submitted. Per the market data, gross margin is 46%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SS Innovations International Inc. (SSII) reported $42.5M in annual revenue (up from $20.6M in FY2024, +105.7% YoY) and -$12.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.9M revenue, -$20.9M net income) through FY2025, SSII scaled operating cash flow to -$18.5M and free cash flow to -$22.2M, backed by $74.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.65% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.20 – $8.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -19.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links are recorded (supply_chain: NONE; butterfly_links: empty). The only sector context provided is the Health Care / Medical-Dental Instruments classification and the Beta of 1.0 per the rating's macro pillar.

  • Key Question #1: Can SSII sustain or expand its -19.3% operating margin and -18.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $42.5M and free cash flow of -$22.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SSII's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SSII Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SS Innovations International Inc. (SSII) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SSII Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SSII Bull vs. Bear Conversation Board — What's Your Call at $2.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SSII 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SSII:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $2.98 (+26.8%)
📌 Pinned Debate

Revenue grew from $5.9M in FY 2023 to $42.5M in FY 2025 while the balance sheet scores 14 / 20 with an Altman Z of 7.47.

Revenue grew from $5.9M in FY 2023 to $42.5M in FY 2025 while the balance sheet scores 14 / 20 with an Altman Z of 7.47.. When you look under the hood at SSII, Fundamental Cash Engine is 5/20 with 46.0% gross margins and -18.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $8.20. My 12M target is $2.98.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SSII's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.00 (-14.9%)
Spot @ $2.35

ROIC of -18.5% and FCF of -$22.2M in FY 2025 leave the fundamental cash engine scoring only 5 / 20 with weak insider and whale flow.

Fading this rally in SSII at $2.35. ROIC of -18.5% and FCF of -$22.2M in FY 2025 leave the fundamental cash engine scoring only 5 / 20 with weak insider and whale flow.. With a beta of 1.0 and the stock sitting at $2.35 (52-wk range $2.20–$8.20), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%